Pharmacokinetic studies of high-dose treosulfan were carried out in seven paediatric patients (age range: 2-15 years) undergoing treosulfan-based conditioning regimen prior to allogeneic haematopoietic SCT. Treosulfan was administered intravenously in a daily dose of 10, 12 or 14 g/m 2 within 2 h. Five out of seven patients received 12 g/m 2 . The plasma concentrations of treosulfan and its quantity eliminated with urine were determined using a validated HPLC method with refractometric detection. Pharmacokinetic parameters were evaluated following first dose using a two-compartment disposition model. These studies demonstrated a dose-dependent increase of area under the concentration (AUC) and maximum concentrationplasma (C max ), but there was variability of these parameters. Rapid clearance of tresoulfan was observed, especially in 10 and 12 g/m 2 doses. Terminal half-life (t 0.5 ) of treosulfan was in the range of 1.71-2.15 h, but the mean percent of parent drug eliminated with urine was 30%, range 16.3-45.4% of the total dose eliminated during the first 12 h after administration. The results of this study confirmed the linear pharmacokinetics of treosulfan, as used in children. However, variability of pharmacokinetic results observed in children studied demonstrates the need for pharmacokinetic evaluation in each paediatric patient undergoing the treosulfan-based preparative regimen, including those using different doses. This approach could enable further reduction of the risk of early and late organ toxicity related to high-dose treosulfan in paediatric patients.
Introduction
Treosulfan (L-threitol-1,4-dimethanesulfonate) is a prodrug of a bifunctional alkylating agent with a structure similar to BU, but it demonstrates less organ toxicity than BU. The monoepoxybutane and diepoxybutane derivatives of treosulfan are responsible for the alkylation of DNA resulting in a misreading of the DNA code, inter-strand cross-links, single-and double-stranded breaks and chromosomal aberrations. 1, 2 Treosulfan has a broad spectrum of antitumour activity and it is registered for the treatment of ovarian carcinoma. [3] [4] [5] [6] In addition, it was demonstrated both in vivo and in vitro that treosulfan reveals an excellent toxicity against all stem cell lines of the BM and this caused that it was recently administered in high doses within the conditioning regimen prior to allogeneic haematopoietic SCT in patients with haematological malignancies. 7 Despite the clinical use of the oral and i.v. formulation, pharmacokinetic data for adult patients are rather scarce. [3] [4] [5] 7, 8 Treosulfan represents linear increase of area under the concentration (AUC) up to 56 g/m 2 in adult patients, whereas other pharmacokinetic parameters, such as halflife, volume of distribution and renal elimination, were independent of dose. 8 According to growing clinical experience, the high-dose treosulfan demonstrates low organ toxicity in paediatric patients when used as a part of the preparative regimen for haematopoietic SCT, 9,10 but until now there were no studies of the pharmacokinetics of the drug in children.
Therefore, the investigation of the clinical pharmacokinetics of treosulfan was performed after 2 h of i.v. infusion of 10, 12 or 14 g/m 2 given as a part of the preparative regimen prior to haematopoietic SCT in children.
Patients and methods

Paediatric patients
Seven children (one girl and six boys) aged between 2 and 15 years (median age: 14), with AML (n ¼ 1), Hodgkin's disease (n ¼ 2), acute biphenotypic leukaemia (AML/ALL) (n ¼ 1), adrenoleukodystrophy (n ¼ 1), Wiskott-Aldrich's syndrome (n ¼ 1) and severe acquired aplastic anaemia (n ¼ 1), were enrolled in the study. Treosulfan (Ovastat, Medac GmbH, Hamburg, Germany) was administered three times at daily doses of 10 (n ¼ 1), 12 (n ¼ 5) or 14 g/m 2 (n ¼ 1) as a part of the preparative regimen prior to allogeneic haematopoietic SCT. Before infusion, treosulfan was dissolved in sterile water for injection to obtain a concentration of 50 mg/ml. After dilution to a defined dose, it was intravenously administered for 2 h. The studies were conducted according to the Declaration of Helsinki Principles, and study protocol was approved by the Ethical Committee at the Poznan University of Medical Sciences. Parents of young patients were informed in writing about all aspects of the study and their permission had to be received prior to the studies.
Determination of treosulfan in plasma and urine by HPLC method Blood samples after single dose were drawn through an indwelling venous access at the following times: before infusion and at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 12.0 and 24.0 h after the start of treosulfan infusion. Blood samples were adjusted to a final pH of 5.5 by the addition of 50 ml of 1 M citric acid per 1 ml of blood immediately after collection to avoid artificial ex vivo degradation of treosulfan and then centrifuged to obtain plasma. The resulting plasma samples were kept frozen at À20 1C until analysis. Urine samples of patients were collected into separate containers over a time course of 24 h after the start of infusion and treated with 50 ml of 1 M citric acid per 1 ml of urine to guarantee a pH o6. The volume of each urine sample was measured and after centrifugation was kept frozen at À20 1C until analysis.
Treosulfan concentrations in children's plasma and urine were determined by a validated reversed-phase HPLC method with refractometric detection. 11 The HPLC system consisted of a quaternary pump model G1311A set at a flow rate of 1 ml/min, degasser model G1322A and refractometric detector model G1362A. The mobile phase was composed of phosphate buffer of pH 5 and an acetonitrile. Barbital was applied as the internal standard. Plasma samples with treosulfan before injection into octadecyl chromatographic column, protected by a guard column, were clarified using centrifugation at 10 000 g for 15 min and microfiltration (cutoff 10 000 Da), and a volume of 100 ml was injected into the HPLC system. Urine samples of 100 ml were diluted with 350 ml water and a volume of 100 ml was injected onto the column. Validation of the method was carried out before using it for pharmacokinetic studies. The linear range of the standard curve of treosulfan was from 10 to 2000 and 50-10 000 mg/ml in plasma and urine, respectively (correlation coefficient r ¼ 0.9997), and covered the levels determined in the biological fluids after infusion of the drug. Limit of detection amounted to 5 mg/ml for plasma and 25 mg/ml for urine. Limit of quantification amounted to 10 and 50 mg/ml in plasma and urine, respectively. Intra-and interday precision and accuracy of the measurement fulfilled analytical criteria devoted to pharmacokinetic studies. Recovery of treosulfan from human plasma after microfiltration, as well as stability in biological fluids after two freeze and thaw cycles, was also calculated.
Pharmacokinetic analysis
The plasma treosulfan concentrations, following first dose, were used to calculate pharmacokinetic parameters based on two-compartment disposition modelling. 11 The Topfit 2.0 software package was applied for the calculations.
Results
Pharmacokinetic parameters
Pharmacokinetic studies of treosulfan administered in the form of 2-h injections were carried out on a group of seven paediatric patients (median age 14 years, range 2-15). Mean concentrations of treosulfan measured in plasma up to 12 h after a dose at 12 g/m 2 were presented in Figure 1 . Peak plasma levels were reached at the finish of the infusion at 2 h. The pharmacokinetic profile of treosulfan in plasma was best fitted by a two-compartment disposition model with first-order elimination process. Increasing of AUC after the administration of a 10, 12 or 14 g/m 2 dose to paediatric patients and variability of the parameter after the 12 g/m 2 dose are presented in Figure 2 . Pharmacokinetic parameters of treosulfan after 2-h infusion into children undergoing myeloablative treatment prior to haematopoietic SCT are summarized in Table 1 . AUC increased with dose and was from 735 mg/l h for 10 g/m 2 to 1309±921 mg/l h for 12 g/m 2 or 1960 mg/l h for 14 g/m 2 ; however, the first and the last results were from single patients. C max also increased with dose and amounted to 271 mg/l for the lowest dose and 632 mg/l for the highest dose administered to children. The mean maximum concentration from five patients amounted to 420±250 mg/l for the 12 g/m 2 dose. Total systemic clearance of treosulfan was in the range from 60 to 385 ml/min with a mean value of 232 ml/min after a dose of 12 g/m 2 . The mean volume of distribution amounted to about 25 l. The terminal half-life of treosulfan was in the range of 1.71-2.15 h, but the mean percent of parent drug eliminated with urine was about 30% of the total dose eliminated during the first 12 h after administration (Table 1) .
Discussion
Treosulfan, a water soluble alkylatying agent, possesses a pronounced effect against haematopoietic cells and a favourable toxicity profile, and therefore the use of highdose treosulfan is increasing in adults 5,7 as well as in paediatric patients 9, 10 undergoing conditioning regimen prior to haematopoietic SCT. Pharmacokinetic data of high-dose treosulfan are rather scarce and exclusively concern adults, whereas there are no data concerning children. We evaluated the pharmacokinetics of treosulfan in children with various haematological malignant (AML, Hodgkin's disease and AML/ALL) and non-malignant (adrenoleukodystrophy, severe acquired aplastic anaemia and Wiskott-Aldrich's syndrome) disorders after the administration of first dose of 10 (n ¼ 1), 12 (n ¼ 5) and 14 g/m 2 (n ¼ 1) of treosulfan as a part of preparative regimen. Increase of AUC with dose was linear (r 2 ¼ 0.999) and corresponds with the data presented in the literature, where at various doses of up to 56 g/m 2 linear correlation between dose and AUC was stated. 8 However, the mean results of AUC after the dose of 12 g/m 2 and also patients treated with 14 g/m 2 dose were greater than those from the literature for the same dose in adults. One patient treated with 12 g/m 2 dose resulted in great values of AUC equal to 2920 mg/l h, which were caused by low values of total systemic clearance of 97 ml/min and also creatinine clearance of 60 ml/min. AUC of the remaining children were in the range of 579-1080 mg/l h (mean 906) and were comparable with the literature data for adult patients. 7 In addition, high value was obtained for child treated with 14 g/m 2 dose. The metabolic acidosis as a result of the methanesulphonic acid formation from treosulfan can cause increasing AUC, because the activation of treosulfan is pH dependent and at pH o6 almost no treosulfan is metabolized. 8 The biological half-life of terminal phase in paediatric patients was in the range of 1.71-2.15 h (Table 1) , which is in good agreement with the previously published clinical reports, however, regarding adults. 3, 4, 7, 8 Fraction of parent compound eliminated with urine was about 30% (range 21-45%) in the group of children treated with 12.0 g/m 2 during the first 12 h, of which 95% eliminated up to 6 h after treosulfan administration. In individual patients treated with 10.0 or 14.0 g/m 2 dose, the eliminated percentage of the drug was 16 and 26%. In addition, these data are comparable with those reported in the literature. [3] [4] [5] 7, 8 Total systemic clearance of treosulfan was in the wide range from 60 to 385 ml/min with a mean value of 232 ml/min after a dose of 12 g/m 2 , similar to the value of 225 ml/min of adult patients treated the same dose 7 ). 3, 4, 7 The small value of 60 ml/min can be the result of reduced creatinine clearance observed in the patient. The volume of distribution with a mean value about 25 l is also comparable with the data from the literature (19.5-34.0 l). 3, 5, 8 
